This study examined levels of hypoxia inducible factor-1α (HIF-1α) protein in 40 laryngeal squamous cell carcinoma specimens using immunohistochemistry. Correlations between HIF-1α immunoreactivity and patient age, tumour lymph node metastasis stage, histological grade (extent of differentiation), and alcohol and smoking history were evaluated. Of the tumour tissues obtained, 35 (87.5%) were located in the glottic area and five (12.5%) in the supraglottic area. All patients were male and aged between 35 and 71 years; 12 (30.0%) presented with lymph node metastases, 24 (60.0%) had cancer classified as T1 or T2, and 16 (40.0%) as high clinical stage (T3 or T4). The pattern of HIF-1α protein localization in tumour tissues, when present, was mixed nuclear/cyto plasmic, with positive HIF-1α expression in 27 patients (67.5%). Differences in HIF-1α levels in samples from different tumour stages and in those with lymph node-positive versus lymph node-negative cancers were statistically significant.
WangWXuGLJiaWD: Expression and correlation of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res2009; 37: 417–425.
2.
McCartyMFBarroso-ArandaJContrerasF: Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses2010; 74: 789–797.
3.
SeeberLMZweemerRPVerheijenRH: Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int2010; 2010: 580971.
4.
SeagrovesTNRyanHELuH: Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol2001; 21: 3436–3444.
5.
BerraERichardDEGothiéE: HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett2001; 491: 85–90.
6.
TalksKLTurleyHGatterKC: The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol2000; 157: 411–421.
7.
ShinoharaETMaityA: Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumour microenvironment. Curr Mol Med2009; 9: 1034–1045.
8.
RohwerNLobitzSDaskalowK: HIF-1α determines the metastatic potential of gastric cancer cells. Br J Cancer2009; 100: 772–781.
9.
CabanillasRRodrigoJPSecadesP: The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol2009; 99: 373–378.
10.
WinterSCShahKAHanC: The relation between hypoxia inducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer2006; 107: 757–766.
11.
KyzasPAStefanouDBatistatouA: Hypoxia-induced tumour angiogenic pathway in head and neck cancer: An in vivo study. Cancer Lett2005; 225: 297–304.
12.
BeasleyNJLeekRAlamM: Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res2002; 62: 2493–2497.
13.
YuLLiuYCuiY: Expression of hypoxia inducible factor-1alpha and its relationship to apoptosis and proliferation in human laryngeal squamous cell carcinoma. J Huazhong Univ Sci Technolog Med Sci2004; 24: 636–638.
14.
SchrijversMLvan der LaanBFde BockGH: Overexpression of intrinsic hypoxia markers HIF1α and CA-IX predict for local recurrence in stage T1–T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys2008; 72: 161–169.
15.
PatelSGShahJP: TNM staging of cancers of the head and neck: Striving for uniformity among diversity. CA Cancer J Clin2005; 55: 242–258.
16.
CaoDHouMGuanYS: Expression of HIF-1alpha and VEGF in colorectal cancer: Association with clinical outcomes and prognostic implications. BMC Cancer2009; 9: 432.
17.
FilliesTWerkmeisterRvan DiestPJ: HIF1- alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer2005; 5: 84.
18.
ReynoldsTYRockwellSGlazerPM: Genetic instability induced by the tumour microenvironment. Cancer Res1996; 56: 5754–5757.
19.
WeidemannAJohnsonRS: Biology of HIF-1α. Cell Death Differ2008; 15: 621–627.
20.
NordsmarkMEriksenJGGebskiV: Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol2007; 83: 389–397.
21.
KaandersJHWijffelsKIMarresHA: Pimonidazole binding and tumour vascularity predict for treatment outcome in head and neck cancer. Cancer Res2002; 62: 7066–7074.
22.
KoukourakisMIGiatromanolakiASivridisE: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys2002; 53: 1192–1202.
23.
WinterSCShahKAHanC: The relation between hypoxia-inducible factor (HIF)-1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer. Cancer2006; 107: 757–766.
24.
AmannTHellerbrandC: GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets2009; 13: 1411–1427.
25.
OganeNYasudaMShimizuM: Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol2010; 14: 23–29.
26.
ZhouSWangSWuQ: Expression of glucose transporter-1 and −3 in the head and neck carcinoma–the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec2008; 70: 189–194.
27.
ZhouSHFanJChenXM: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck2009; 31: 1624–1633.
